HomeFinanceTerns Pharmac...

Terns Pharmaceuticals Inc. (TERN) Stock is Just Right Size-Neither Too Big Nor Too Small

JMP Securities raised the price target for the Terns Pharmaceuticals Inc. (NASDAQ:TERN) stock to “a Mkt outperform”. The rating was released on February 14, 2023, according to finviz. The research report from H.C. Wainwright has initiated the stock to Neutral, with a price target set at $6. The stock was resumed by Goldman, who disclosed in a research note on September 14, 2021, to Buy and set the price objective to $21. In their research brief published March 02, 2021, JP Morgan analysts initiated the Terns Pharmaceuticals Inc. stock to Overweight with a price target of $32.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Terns Pharmaceuticals Inc. (NASDAQ:TERN) raised 1.61% to close Friday’s market session at $10.09, higher as compared to yesterday’s close. The stock price fluctuated between $9.81 and $10.36 throughout the trading session with the volume trading being 992095 shares, which represented a significant variation when compared to the three months average volume of 346.28K shares. The firm’s stock price fluctuated 10.64% within the last five trades and -2.04% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 57.17% in the last 6 months and 54.28% was added to its value over the previous 3 months. TERN stock is trading at a margin of -0.65%, 6.85% and 70.66% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


As of the close of trading, TERN deals in the Healthcare domain. The stock is trading -11.80 percent below its 52-week high and 595.86 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 162.24. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Terns Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $388.59 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 388.59 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 2.12, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 2.48 percent of Terns Pharmaceuticals Inc. shares are owned by insiders, and 98.20 percent are held by financial institutions. Lu Hongbo, the Director at Terns Pharmaceuticals Inc. (TERN) has bought 758,620 shares of firm on Dec 23 at a price of $7.25 against the total amount of $5.5 million. In another inside trade, Vivo Opportunity, LLC, 10% Owner of Terns Pharmaceuticals Inc. (NASDAQ:TERN) bought 758,620 shares of the firm on Dec 23 for a total worth of $5.5 million at a price of $7.25. An inside trade which took place on Dec 23, Director of Terns Pharmaceuticals Inc. ORBIMED ADVISORS LLC bought 137,931 shares of firm against total price of $1.0 million at the cost of $7.25 per share.



Please enter your comment!
Please enter your name here

Recent Post